Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 17/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4143683 | 0.89 | HTR1A (0.41) | HTR1AHTR2AHTR2CSLC6A4 | |
| SCHEMBL3567298 | 0.77 | KDM4E (0.41) | ALDH1A1HTTKMT2A | |
| SCHEMBL3555203 | 0.75 | HTR2A (0.62) | HTR1AHTR2AHTR2CSLC6A4 | |
| SCHEMBL13437110 | 0.74 | HTR1A (0.56) | HTR1A | |
| SCHEMBL2298747 | 0.74 | HTR2A (0.41) | HTR2AHTR2C | |
| SCHEMBL6992310 | 0.73 | HTR2C (0.39) | HTR2AHTR2C | |
| SCHEMBL2297610 | 0.73 | SMN1; SMN2 (0.53) | ALDH1A1KMT2AHTR2AHTR2C | |
| Adipic Acid SCHEMBL3558210 | 0.72 | ALDH1A1 (0.53) | HTR1AALDH1A1HTTKMT2AHTR2A | |
| SCHEMBL4133764 | 0.71 | HTR2C (0.36) | HTR2AHTR2C | |
| SCHEMBL4738514 | 0.71 | HTR2A (0.34) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | VENKATESAN ARANAPAKAM MUDUMBAI | 2009-02-26 | — | — | US | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1641785-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIBITORS | Wyeth (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | WYETH | 2005-03-17 | — | — | US | disclosed |
| WO-2004099191-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIB ITORS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | TPH1, TPH2, HTR2C | HTR1A 12/4885ALDH1A1 828/4885HTT 273/4885 |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | TPH1, TPH2, HTR2C | HTR1A 12/4885ALDH1A1 828/4885HTT 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.